Giuseppe Tonini

Research interests

Publications

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00469-2

• Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.05.801

• Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

  Journal of Experimental & Clinical Cancer Research · 2020 · https://doi.org/10.1186/s13046-020-01601-2

• The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

  British Journal of Cancer · 2020 · https://doi.org/10.1038/s41416-020-0894-7

• Gut Microbiota and Cancer: From Pathogenesis to Therapy

  Cancers · 2019 · 10.3390/cancers11010038

• Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis

  Scientific Reports · 2017 · https://doi.org/10.1038/s41598-017-08121-8

• Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study

  Oncotarget · 2017 · https://doi.org/10.18632/oncotarget.20168

• Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

  Modern Pathology · 2015 · https://doi.org/10.1038/modpathol.2015.98

• FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00122-9

• Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1403108

• Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mdr623

• Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

  British Journal of Cancer · 2012 · https://doi.org/10.1038/bjc.2012.375

• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

  The Lancet Oncology · 2010 · https://doi.org/10.1016/s1470-2045(10)70130-3

• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  British Journal of Cancer · 2009 · https://doi.org/10.1038/sj.bjc.6605177

• PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.20.2796

• Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

  The Lancet Oncology · 2008 · https://doi.org/10.1016/s1470-2045(07)70383-2

• High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

  The Oncologist · 2008 · https://doi.org/10.1634/theoncologist.2008-0181

• Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer

  European Journal of Cancer · 2008 · https://doi.org/10.1016/j.ejca.2008.05.017

• Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2006.08.1844

• Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr)

  Journal of Endocrinological Investigation · 2006 · 10.1007/bf03344156

• Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

  Annals of Oncology · 2003 · 10.1093/annonc/mdg417

• Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

  PubMed · 2003

• Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

  PubMed · 2002

• Italian cross-sectional growth charts for height, weight and BMI (6–20 y)

  European Journal of Clinical Nutrition · 2002 · 10.1038/sj.ejcn.1601314

• A Dosage Sensitive Locus at Chromosome Xp21 Is Involved in Male to Female Sex Reversal

  Obstetrical & Gynecological Survey · 1995 · 10.1097/00006254-199502000-00020

• A dosage sensitive locus at chromosome Xp21 is involved in male to female sex reversal

  Nature Genetics · 1994 · 10.1038/ng0894-497

Current projects

No projects listed.